Abstract Adjuvant chemotherapy is benefit for high-risk stage II and stage III colon cancer after curative resection. But, the optimal time between surgical and initiation of adjuvant chemotherapy remains unclear. Moreover, no study of efficacy with different lengths of adjuvant chemotherapy has appeared. This study was aimed to identify association between time (initiation and length) and oncological outcomes of adjuvant chemotherapy on the stages II and III colon cancer patients. A total of 406 high-risk stages II and III colon cancer patients were retrospectively enrolled in prospectively collected data. They were categorized into three groups representing chemotherapy initiation time: less than 4 weeks (group 1), 4 to 6 weeks (group 2), and more than 6 weeks (group 3). They were categorized into two groups representing chemotherapy length time : less than 200 days (group 1a) and more than 200 days (group 2a). The 5-year disease-free survival (DFS) rates were 74.97 % in group 1, 76.94 % in group 2, and 63.97 % in group 3 (p>0.05). The 5-year DFS rates were 75.49 % in the group that received adjuvant chemotherapy within 6 weeks and 63.97 % in the group that received adjuvant chemotherapy >6 weeks (p=0.0539). The 5-year DFS rates were 77.21 % in group 1a and 81.82 % in group 2a (p>0.05). Adjuvant chemotherapy should be safely offered within 6 weeks after surgical excision in patients with colon cancer after considering the patient's general physical condition and hematological factors, even if the chemotherapy length is prolonged.
Introduction
Colorectal cancer is the second most common cancer in Korean men and the third most common in women [1] . The mainstay of colon cancer treatment is surgical resection. However, 40-50 % of patients eventually develop recurrence or die from metastasis [2, 3] . Several large, randomized clinical trials have reported that patients who undergo adjuvant chemotherapy after curative resection of colorectal cancer have better prognoses than those who undergo surgical treatment only [4, 5] . Stage II with high-risk factor and stage III colon cancer patients are routinely recommended to undergo adjuvant chemotherapy after surgical resection [6, 7] . However, the optimal time between surgical and initiation of adjuvant chemotherapy remains unclear. Some studies have reported that adjuvant chemotherapy commenced within 8 weeks after surgical resection results in a better prognosis than chemotherapy commenced after 8 weeks [8] [9] [10] [11] [12] . Thus, most surgical oncologists tend to start adjuvant chemotherapy as soon as possible, no later than 6-8 weeks after surgery.
No difference was observed in the efficacies of 6-and 12-month chemotherapy durations in a 5-fluorouracil (5-FU)/ levamisole adjuvant chemotherapy study [13] . In addition, no difference was found between 6-and 9-month chemotherapy durations in the GERCOR C96.1 trial [14] . The current recommendation for the duration of adjuvant chemotherapy in patients with colon cancer is 6 months, which is 12 cycles of the FOLFOX regimen and 6 cycles of the 5-FU/leucovorin (FL) regimen. Nevertheless, for various reasons (side effects and patient-and hospital-specific factors), regular chemotherapy cycles are often completed after more than 6 months. No study of efficacy with different lengths of adjuvant chemotherapy has appeared.
Thus, we evaluated the efficacy of adjuvant chemotherapy in terms of initiation time and length.
Materials and Methods

Subjects
This retrospective study included 406 patients with colon cancer who were given FOLFOX4 or FL chemotherapy after radical surgery in the Department of Surgery, Busan Paik Hospital, Inje University College of Medicine between January 2005 and December 2010. The patients were classified using the 6th edition of the American Joint Committee on Cancer TNM staging system. We enrolled stage II with high-risk factor and stage III colon cancer patients and based on the 2013 National Comprehensive Cancer Network (NCCN) guidelines.
Colon cancer was defined as cancer in which the lower tumor margin was located in the upper part of the peritoneum, and the high-risk stage II group had to have at least one of the following features: T4a/4b stage; tumor perforation; bowel obstruction; a poorly differentiated tumor; or venous, perineural, or lymphatic invasion.
Chemotherapy Methods and Follow-Up Observations
FOLFOX4 Chemotherapy
Leucovorin (LV; 200 mg/m 2 /day) was administered intravenously (IV) for 2 h. Then, a bolus IV infusion of 400 mg/m 2 5-FU was administered, followed by IV administration of 600 mg/m 2 5-FU continuously for 22 h. This regimen was continued for 2 days. Oxaliplatin (85 mg/m 2 ) was infused for 2 h only on day 1. A prophylactic antiemetic agent and adequate fluid were infused on chemotherapy days 1 and 2. This regimen was administered every 2 weeks for a total of 12 cycles.
FL Chemotherapy
A bolus IVof 20 mg/m 2 LV was administered, followed by IV continuous administration of 425 mg/m 2 5-FU for 2 h. This regimen was continued daily for 5 days, every 4 weeks for a total of 6 cycles.
Follow-Up
Patients were followed up every 3 months for the first 2 years after surgery and every 6 months thereafter for 3 years. History, physical features, and serum carcinoembryonic antigen level were checked at each follow-up visit. Chest X-ray and abdominopelvic computed tomography scans were performed to assess chemotherapy efficacy every 3 months and every 6 months (respectively) after completion of chemotherapy. Colonoscopy was performed annually. Recurrence was identified by imaging studies and colonoscopy and was confirmed by colonoscopic or percutaneous biopsy. Radiologically identified tumor growth at the operative site was considered to indicate recurrence when histological confirmation was not possible.
Patient Categorization
Chemotherapy Initiation Time After Surgery 
Results
Clinicopathological Data
Totals of 275, 90, and 59 patients started chemotherapy within 4 weeks (group 1), within 4-6 weeks (group 2), and after 6 weeks (group 3), respectively. No significant difference in any of age, sex, T stage, N stage, or histological differentiation was observed among the groups. Group 3 patients underwent more FL than FOLFOX chemotherapy compared to the other groups (p=0.014) ( Table 1) . Patients who had completed chemotherapy were divided into two groups; those who completed within 200 days (group 1a; n=194) and those who completed in >200 days (group 2a; n=159). No significant difference was observed in terms of age, sex, T stage, or histological differentiation between the two groups. Significantly more lymph node metastasis (p<0.0001) and significantly more FOLFOX than FL chemotherapy (p<0.0001) were observed in group 2a than group 1a (Table 1) . Prolonged chemotherapy (>200 days) was mainly attributable to neutropenia (100 patients) or hospital factors (38 patients) ( Table 2 ).
Analysis of DFS and Prognostic Factors
The prognostic factors for DFS upon univariate analysis were T stage (p=0.0187) and N stage (p<0.0001). The prognostic factors for DFS upon multivariate analysis were also T stage (p=0.0232) and N stage (p<0.0001) ( Table 3) .
The 5-year DFS rates were 74.97 % in group 1, 76.94 % in group 2, and 63.97 % in group 3 (p>0.05) (Fig. 1) . The 5-year DFS rates were 75.49 % in the group that received adjuvant chemotherapy within 6 weeks after surgery and 63.97 % in the group that received adjuvant chemotherapy >6 weeks after surgery. The 5-year DFS rates in the two groups differed with borderline significance (p=0.0539) (Fig. 1) . The 5-year DFS rates were 77.21 % in group 1a and 81.82 % in group 2a (p>0.05) (Fig. 2) .
Discussion
Most surgical oncologists tend to start adjuvant chemotherapy as soon as possible after resection, based on reports suggesting that surgery promotes the expression of oncogenic growth factors, such as transforming growth factor, which results in tumor growth [15, 16] . Furthermore, the risk of metastasis may be elevated because of due the decrease in angiogenesis inhibitors triggered by tumor resection [17, 18] .
No clear NCCN guidelines indicate when adjuvant chemotherapy should be initiated in patients with colon cancer. Nevertheless, several large-scale studies conducted to demonstrate the efficacy of adjuvant chemotherapy started treatment within 42 days [19] [20] [21] [22] . Only 10 % of all patients with breast cancer in the SEER-Medicare database received chemotherapy 3 months after surgery, and their overall mortality hazard ratio (HR) was 1. [9] . Numerous studies have reported that patients who start adjuvant chemotherapy 6-8 weeks after surgery have better survival rates than those who do not [24] [25] [26] . We analyzed the 5-year DFS rates of patients who started chemotherapy within 4 weeks (group 1, 80.26 %), within 4-6 weeks (group 2, 83.03 %), and >6 weeks (group 3, 70.08 %) after resection, but found no differences (p=0.2096). However, the 5-year group 3 DFS rate tended to be lower than those of groups 1 or 2, so we divided the groups into two subgroups of within 6 weeks and >6 weeks after surgery. The results showed that patients who started adjuvant chemotherapy within 6 weeks tended to have a higher 5-year DFS rate than those who started it later. This result is similar to that of other studies [24] [25] [26] , reporting that it is beneficial to start adjuvant chemotherapy within 6 weeks after surgery. However, as previous studies and our study show, initiating chemotherapy too early does not guarantee a satisfactory 5-year DFS rate. Goldman et al. [27] reported that patients who undergo gastrointestinal surgery usually have poor oral intake abilities, which could affect the immune system, suggesting that initiating chemotherapy too early could result in numerous side effects. Moreover, chemotherapy initiated immediately after surgery (in an animal study) increased the incidence of anastomotic leakage [28] . Moertel et al. reported that 12 months of adjuvant chemotherapy with 5-FU plus levamisole yielded excellent outcomes [29] . Thereafter, the Intergroup trial 0089 (INT-0089) and the Groupe Cooperateur Multidisciplinaire en Oncologie trial found no difference in efficacy among 6, 9, and 12 months of 5-FU/LV [13, 14] . The ideal duration for adjuvant chemotherapy in patients with colon cancer is 6 months, which is 12 cycles of FOLFOX and 6 of FL. Patients with colon cancer receiving adjuvant chemotherapy may experience numerous hematological, gastrointestinal, and dermatological side effects. Chemotherapy cycles are often delayed by patient or hospital factors or side effects, rendering patients' anxious. No studies have been conducted on chemotherapy length; thus, we analyzed data from patients who completed chemotherapy within or >200 days after surgical resection and found no difference in the 5-year DFS rate (76.69 vs. 83.24 %, p= 0.1337) between the two groups. These results could suggest that a longer adjuvant chemotherapy length might have no effect on prognosis.
There are a few limitations to our study. First, this was a retrospective study based on clinical records; thus, some unrecorded factors may have affected survival rates, and the reasons for prolonged chemotherapy duration may be inadequately clear on records. Second, this was a nonrandomized non-prospective study, for ethical reasons.
In conclusion, starting adjuvant chemotherapy within 6 weeks after surgical excision in patients with colon cancer could lead to a better oncological outcome, even considering postoperative complications and general physical condition. Moreover, a longer adjuvant chemotherapy length might have no effect on prognosis. Therefore, adjuvant chemotherapy should be safely offered after considering the patient's general physical condition and hematological factors, even if the chemotherapy length is prolonged.
